Newswise — Hackensack Meridian Hackensack University Medical Center, Center for Memory Loss and Brain Health will be participating in a multicenter clinical trial to study the safety and efficacy of escitalopram, an antidepressant, for the treatment of agitation related to Alzheimer’s disease. This study is sponsored by the National Institute on Aging. Johns Hopkins University is the principal site and Hackensack University Medical Center will begin enrolling patients in the study starting in September 2021.
Alzheimer’s disease is a neurodegenerative condition that results in weakened brain connections and loss of brain cells. These problems cause dementia, which may include problems with memory, thinking, mood and behavior. Mood and behavior problems may include sudden outbursts of anger, aggression or agitation.
Patients may be eligible for the study if they have received a…
